Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 11
Submit an article Journal homepage
794
Views
61
CrossRef citations to date
0
Altmetric
Reviews

Targeting of HDAC8 and investigational inhibitors in neuroblastoma

Ina Oehme German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]
,
Hedwig E Deubzer German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]; University of Heidelberg, Department of Pediatric Oncology, Hematology and Immunology, INF 430, D-69120 Heidelberg, Germany
,
Marco Lodrini German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]; University of Heidelberg, Department of Pediatric Oncology, Hematology and Immunology, INF 430, D-69120 Heidelberg, Germany
,
Till Milde German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]
&
Olaf Witt German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany +49 6221 423388; +49 6221 423277; [email protected]
Pages 1605-1617 | Published online: 28 Sep 2009

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

S. M. Esther Rubavathy, Kandhan Palanisamy, S. Priyankha, Ramasamy Thilagavathi, Muthuramalingam Prakash & Chelliah Selvam. (2023) Discovery of novel HDAC8 inhibitors from natural compounds by in silico high throughput screening. Journal of Biomolecular Structure and Dynamics 41:19, pages 9492-9502.
Read now
Sergio Valente & Antonello Mai. (2014) Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013). Expert Opinion on Therapeutic Patents 24:4, pages 401-415.
Read now
Geneviève P Delcuve, Dilshad H Khan & James R Davie. (2013) Targeting class I histone deacetylases in cancer therapy. Expert Opinion on Therapeutic Targets 17:1, pages 29-41.
Read now
Praveen Rajendran, David E. Williams, Emily Ho & Roderick H. Dashwood. (2011) Metabolism as a key to histone deacetylase inhibition. Critical Reviews in Biochemistry and Molecular Biology 46:3, pages 181-199.
Read now
Paul A Marks. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opinion on Investigational Drugs 19:9, pages 1049-1066.
Read now

Articles from other publishers (56)

Mohammed Mukhtar Yusif. (2023) Targeting cancers and metabolic disorders: The prospects of combining HDAC8 inhibitor and activator. European Journal of Medicinal Chemistry Reports 7, pages 100097.
Crossref
Ji Yoon Kim, Hayoung Cho, Jung Yoo, Go Woon Kim, Yu Hyun Jeon, Sang Wu Lee & So Hee Kwon. (2023) HDAC8 Deacetylates HIF-1α and Enhances Its Protein Stability to Promote Tumor Growth and Migration in Melanoma. Cancers 15:4, pages 1123.
Crossref
Abdelrahman Hamdi, Walaa M. Elhusseiny, Dina I.A. Othman, Abdullah Haikal, Ahmed H. Bakheit, Adel S. El-Azab, Mohamed H.M. Al-Agamy & Alaa A.-M. Abdel-Aziz. (2022) Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study. European Journal of Medicinal Chemistry 244, pages 114827.
Crossref
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, Sandra Gemma, Stefania Butini & Giuseppe Campiani. (2022) A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors. International Journal of Molecular Sciences 23:17, pages 10014.
Crossref
Sabine A. Stainczyk & Frank Westermann. (2021) Neuroblastoma—Telomere maintenance, deregulated signaling transduction and beyond. International Journal of Cancer 150:6, pages 903-915.
Crossref
Alessandro Mormino, Germana Cocozza, Giulia Fontemaggi, Sergio Valente, Vincenzo Esposito, Antonio Santoro, Giovanni Bernardini, Angela Santoni, Francesco Fazi, Antonello Mai, Cristina Limatola & Stefano Garofalo. (2021) Histone‐deacetylase 8 drives the immune response and the growth of glioma. Glia 69:11, pages 2682-2698.
Crossref
Minal Mahajan, Snehal Suryavanshi, Shovonlal Bhowmick, Fatmah Ali Alasmary, Tahani Mazyad Almutairi, Md Ataul Islam & Ruchika Kaul-Ghanekar. (2021) Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity. Biophysical Chemistry 273, pages 106588.
Crossref
Beatrice Ferrari, Elisa Roda, Erica Cecilia Priori, Fabrizio De Luca, Angelica Facoetti, Mauro Ravera, Federico Brandalise, Carlo Alessandro Locatelli, Paola Rossi & Maria Grazia Bottone. (2021) A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Frontiers in Neuroscience 15.
Crossref
Atif Zafar, Wei Wang, Gang Liu, Xinjie Wang, Wa Xian, Frank McKeon, Jennifer Foster, Jia Zhou & Ruiwen Zhang. (2020) Molecular targeting therapies for neuroblastoma: Progress and challenges. Medicinal Research Reviews 41:2, pages 961-1021.
Crossref
Taranom Mobasheri, Elham Rayzan, Mahsima Shabani, Mina Hosseini, Ghanbar Mahmoodi Chalbatani & Nima Rezaei. (2020) Neuroblastoma‐targeted nanoparticles and novel nanotechnology‐based treatment methods. Journal of Cellular Physiology 236:3, pages 1751-1775.
Crossref
Baiqi Wang, Lili Xu, Ju Zhang, Xinru Cheng, Qianya Xu, Jian Wang & Fengxia Mao. (2020) LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p. Biomedicine & Pharmacotherapy 129, pages 110268.
Crossref
Muhammad Murtaza Hassan, Johan Israelian, Nabanita Nawar, Giovanni Ganda, Pimyupa Manaswiyoungkul, Yasir S. Raouf, David Armstrong, Abootaleb Sedighi, Olasunkanmi O. Olaoye, Fettah Erdogan, Aaron D. Cabral, Fabrizio Angeles, Rabia Altintas, Elvin D. de Araujo & Patrick T. Gunning. (2020) Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. Journal of Medicinal Chemistry 63:15, pages 8634-8648.
Crossref
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, Markus Schweipert, Jessica D. Hess, Luca Henze Macias, Piotr Mrowka, Renato J. Aguilera, Jun-yong Choe, Franz-Josef Meyer-Almes & C.S. Ramaa. (2020) Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorganic Chemistry 100, pages 103934.
Crossref
Nguyễn Cường Quốc, Trần Quang Đệ, Nguyễn Trọng Tuân & Bùi Thị Bửu Huê. (2020) Nghiên cứu tương tác của vorinostat với enzyme HDAC8 (1T67) bằng Autodock. Can Tho University Journal of Science 56:6, pages 77.
Crossref
Kalpana Tilekar, Neha Upadhyay, Niklas Jänsch, Markus Schweipert, Piotr Mrowka, F.J. Meyer-Almes & C.S. Ramaa. (2020) Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. Bioorganic Chemistry 95, pages 103522.
Crossref
Sudhan Debnath, Tanusree Debnath, Samhita Bhaumik, Swapan Majumdar, Arunasree M. Kalle & Vema Aparna. (2019) Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation. Scientific Reports 9:1.
Crossref
Suvankar Banerjee, Nilanjan Adhikari, Sk Abdul Amin & Tarun Jha. (2019) Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. European Journal of Medicinal Chemistry 164, pages 214-240.
Crossref
Beatrice Rangone, Beatrice Ferrari, Valentina Astesana, Irene Masiello, Paola Veneroni, Ilaria Zanellato, Domenico Osella & Maria Grazia Bottone. (2018) A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells. Life Sciences 210, pages 166-176.
Crossref
Fiona R. Kolbinger, Emily Koeneke, Johannes Ridinger, Tino Heimburg, Michael Müller, Theresa Bayer, Wolfgang Sippl, Manfred Jung, Nikolas Gunkel, Aubry K. Miller, Frank Westermann, Olaf Witt & Ina Oehme. (2018) The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. Archives of Toxicology 92:8, pages 2649-2664.
Crossref
Kaat Durinck & Frank Speleman. (2018) Epigenetic regulation of neuroblastoma development. Cell and Tissue Research 372:2, pages 309-324.
Crossref
Luz Jubierre, Carlos Jiménez, Eric Rovira, Aroa Soriano, Constantino Sábado, Luis Gros, Anna Llort, Raquel Hladun, Josep Roma, Josep Sánchez de Toledo, Soledad Gallego & Miguel F. Segura. (2018) Targeting of epigenetic regulators in neuroblastoma. Experimental & Molecular Medicine 50:4, pages 1-12.
Crossref
Ahmed T. Negmeldin, Joseph R. Knoff & Mary Kay H. Pflum. (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. European Journal of Medicinal Chemistry 143, pages 1790-1806.
Crossref
Hazem Abdelkarim, Raghupathi Neelarapu, Antonett Madriaga, Aditya S. Vaidya, Irida Kastrati, Bhargava Karumudi, Yue-ting Wang, Taha Y. Taha, Gregory R. J. Thatcher, Jonna Frasor & Pavel A. Petukhov. (2017) Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors. ChemMedChem 12:24, pages 2030-2043.
Crossref
Vijaya Rao Pidugu, Nagendra Sastry Yarla, Anupam Bishayee, Arunasree M. Kalle & Alapati Krishna Satya. (2017) Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells. Apoptosis 22:11, pages 1394-1403.
Crossref
Ahmed T. Negmeldin & Mary Kay H. Pflum. (2017) The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. Bioorganic & Medicinal Chemistry Letters 27:15, pages 3254-3258.
Crossref
Gang Zhao, Guoliang Wang, Hongmin Bai, Tiandong Li, Fanghe Gong, Huan Yang, Jinchong Wen & Weimin Wang. (2017) Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137. European Journal of Pharmacology 802, pages 20-26.
Crossref
Hui Zhang, Yu-Ping Shang, Hong-ying Chen & Jun Li. (2017) Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatology Research 47:2, pages 149-159.
Crossref
Mee-Young Ahn & Jung-Hoon Yoon. (2017) Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. Oncology Reports 37:1, pages 540-546.
Crossref
Gonzalo Lopez & Raphael E. Pollock. 2017. HDAC/HAT Function Assessment and Inhibitor Development. HDAC/HAT Function Assessment and Inhibitor Development 365 374 .
Alokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, Ina Oehme, Johanna Senger, Olaf Witt, Wolfgang Sippl & Manfred Jung. (2016) Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Future Medicinal Chemistry 8:13, pages 1609-1634.
Crossref
Ying Wang, Po Xu, Jun Yao, Ruina Yang, Zhenguo Shi, Xiaojuan Zhu, Xiaoshan Feng & Shegan Gao. (2015) RETRACTED ARTICLE: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8. Targeted Oncology 11:2, pages 197-207.
Crossref
Wenjing Gong, Ruibo Wu & Yingkai Zhang. (2015) Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An Ab initio QM/MM molecular dynamics study . Journal of Computational Chemistry 36:30, pages 2228-2235.
Crossref
Song Zhang, Weibin Huang, Xiaonan Li, Zhicheng Yang & Binghong Feng. (2015) Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors. Chemical Biology & Drug Design 86:4, pages 795-804.
Crossref
Gonzalo Lopez, Kate Lynn J. Bill, Hemant Kumar Bid, Danielle Braggio, Dylan Constantino, Bethany Prudner, Abeba Zewdu, Kara Batte, Dina Lev & Raphael E. Pollock. (2015) HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLOS ONE 10:7, pages e0133302.
Crossref
Rosaria BenedettiMariarosaria ConteLucia Altucci. (2015) Targeting Histone Deacetylases in Diseases: Where Are We?. Antioxidants & Redox Signaling 23:1, pages 99-126.
Crossref
Alokta Chakrabarti, Ina Oehme, Olaf Witt, Guilherme Oliveira, Wolfgang Sippl, Christophe Romier, Raymond J. Pierce & Manfred Jung. (2015) HDAC8: a multifaceted target for therapeutic interventions. Trends in Pharmacological Sciences 36:7, pages 481-492.
Crossref
Matthew S. StrattonTimothy A. McKinsey. (2015) Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. Biochemistry and Cell Biology 93:2, pages 149-157.
Crossref
Maria A. Cavasin, Kurt R. Stenmark & Timothy A. McKinsey. (2015) Emerging Roles for Histone Deacetylases in Pulmonary Hypertension and Right Ventricular Remodeling (2013 Grover Conference series). Pulmonary Circulation 5:1, pages 63-72.
Crossref
Guozhi Tang, Jason C. Wong, Weixing Zhang, Zhanguo Wang, Nan Zhang, Zhenghong Peng, Zhenshan Zhang, Yiping Rong, Shijie Li, Meifang Zhang, Lingjie Yu, Teng Feng, Xiongwen Zhang, Xihan Wu, Jim Z. Wu & Li Chen. (2014) Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors. Journal of Medicinal Chemistry 57:19, pages 8026-8034.
Crossref
Jörn Lötsch, Gisbert Schneider, Daniel Reker, Michael J. Parnham, Petra Schneider, Gerd Geisslinger & Alexandra Doehring. (2013) Common non-epigenetic drugs as epigenetic modulators. Trends in Molecular Medicine 19:12, pages 742-753.
Crossref
Ina OehmeJan-Peter LinkeBarbara C. BöckTill MildeMarco LodriniBettina HartensteinInga WiegandChristian EckertWilfried RothMarcel KoolSylvia KadenHermann-Josef GröneJohannes H. SchulteSven LindnerAnne Hamacher-Brady, Nathan R. Brady, Hedwig E. DeubzerOlaf Witt. (2013) Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences 110:28.
Crossref
Chi-qi Chen, Kang Yu, Qing-xian Yan, Chong-yun Xing, Yi Chen, Zhuang Yan, Yi-fen Shi, Ke-Wen Zhao & Shen-meng Gao. (2013) Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class Ι histone deacetylases. Carcinogenesis 34:7, pages 1442-1449.
Crossref
Ying-Chen Yang, Chia-Nan Chen, Carol-Imei Wu, Wei-Jan Huang, Tsun-Yung Kuo, Ming-Chung Kuan, Tung-Hu Tsai, Jing-Shi Huang & Chung-Yang Huang. (2013) NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-18.
Crossref
Maria New, Heidi Olzscha & Nicholas B. La Thangue. (2012) HDAC inhibitor-based therapies: Can we interpret the code?. Molecular Oncology 6:6, pages 637-656.
Crossref
Aditya Sudheer Vaidya, Raghupathi Neelarapu, Antonett Madriaga, He Bai, Emma Mendonca, Hazem Abdelkarim, Richard B. van Breemen, Sylvie Y. Blond & Pavel A. Petukhov. (2012) Novel histone deacetylase 8 ligands without a zinc chelating group: Exploring an ‘upside-down’ binding pose. Bioorganic & Medicinal Chemistry Letters 22:21, pages 6621-6627.
Crossref
Xian-Chao Cheng, Run-Ling Wang, Zhen-Ke Dong, Jing Li, Yao-Yuan Li & Rong-Rong Li. (2012) Design, synthesis and evaluation of novel metalloproteinase inhibitors based on l-tyrosine scaffold. Bioorganic & Medicinal Chemistry 20:19, pages 5738-5744.
Crossref
Wei-Jan Huang, Yi-Ching Wang, Shi-Wei Chao, Chen-Yui Yang, Liang-Chieh Chen, Mei-Hsiang Lin, Wen-Chi Hou, Mei-Yu Chen, Tai-Lin Lee, Ping Yang & Chung-I Chang. (2012) Synthesis and Biological Evaluation of ortho -Aryl N -Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors . ChemMedChem 7:10, pages 1815-1824.
Crossref
S Spiegel, S Milstien & S Grant. (2011) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31:5, pages 537-551.
Crossref
Omar Khan & Nicholas B La Thangue. (2011) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology & Cell Biology 90:1, pages 85-94.
Crossref
Ju-Hee Lee, Megan L. Choy & Paul A. Marks. 2012. Histone Deacetylase Inhibitors as Cancer Therapeutics. Histone Deacetylase Inhibitors as Cancer Therapeutics 39 86 .
Ingrid Øra & Angelika Eggert. (2011) Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research. Seminars in Cancer Biology 21:4, pages 217-228.
Crossref
Raghupathi Neelarapu, Denise L. Holzle, Subash Velaparthi, He Bai, Michael Brunsteiner, Sylvie Y. Blond & Pavel A. Petukhov. (2011) Design, Synthesis, Docking, and Biological Evaluation of Novel Diazide-Containing Isoxazole- and Pyrazole-Based Histone Deacetylase Probes. Journal of Medicinal Chemistry 54:13, pages 4350-4364.
Crossref
Jinhong Feng, Fanbo Jing, Hao Fang, Lichuan Gu & Wenfang Xu. (2011) Expression, purification, and <i>S</i>-nitrosylation of recombinant histone deacetylase 8 in <i>Escherichia coli </i>. BioScience Trends 5:1, pages 17-22.
Crossref
André Fischer, Farahnaz Sananbenesi, Alison Mungenast & Li-Huei Tsai. (2010) Targeting the correct HDAC(s) to treat cognitive disorders. Trends in Pharmacological Sciences 31:12, pages 605-617.
Crossref
Paul A. Marks. (2010) Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1799:10-12, pages 717-725.
Crossref
Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp-Schneider, Marc Remke, Paul Northcott, Hedwig E. Deubzer, Marco Lodrini, Michael D. Taylor, Andreas von Deimling, Stefan Pfister & Olaf Witt. (2010) HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research 16:12, pages 3240-3252.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.